CEO of COSMOS HEALTH Buys 218,000 Shares Under Debt‑Swap Deal, Signals Confidence in Turnaround Effort

Insider Buying Continues Amid a Debt‑Exchange Deal

COSMOS HEALTH’s latest 4‑form filing shows Chief Executive Officer Siokas Grigorios purchasing 218,447 shares at $0.206 each—about $45 000 worth—under a debt‑exchange agreement that has lifted his holdings to 13.48 million shares. The transaction is part of a broader wave of insider buying that has unfolded over the past month, with other senior officers also acquiring substantial blocks. While the price move is modest, the deal signals confidence from the company’s leadership during a period of strategic repositioning.

What Investors Should Note

The share price remains near its 52‑week low of $0.195, and the stock has trended sharply down—over 18 % in a week and more than 30 % in the month. Grigorios’ purchase, executed at a price only 3 bps below the market close, suggests a belief that the current valuation is undervalued relative to the company’s pipeline and planned acquisitions. Moreover, the debt‑exchange structure may help free capital for the announced intent to acquire Doc Pharma S.A., potentially adding a manufacturing arm that could accelerate product commercialization. Investors watching the next earnings cycle should monitor whether this infusion of capital and expanded capabilities can turn the steep decline into a rebound.

A Profile of Siokas Grigorios

Grigorios’ insider activity over the past year has been consistent and bullish. He has executed a series of sizable purchases—ranging from 90,000 to 2.35 million shares—typically at prices well below the prevailing market rate. His most recent block of 2.35 million shares (on 2026‑05‑19) was followed by a restricted‑stock unit sale of the same amount, indicating a strategy of leveraging debt to acquire equity. This pattern of using debt‑exchange transactions to build stake is repeated in the current 218,447‑share buy, underscoring a long‑term commitment to the company. The CEO’s cumulative holdings now exceed 13 million shares, giving him substantial voting power and aligning his interests closely with shareholders.

Implications for the Company’s Future

The insider buying, coupled with the announced acquisition of a GMP‑licensed manufacturer, points to a strategic shift from purely R&D to integrated production and commercialization. If successful, this could stabilize revenue streams and improve margins—critical for a company that has struggled with valuation volatility. The debt‑exchange mechanism also demonstrates a creative approach to capital management, potentially preserving cash for growth initiatives while rewarding the CEO and other executives.

For investors, the key questions are: will the new manufacturing capability translate into marketable products, and can the company reverse its steep price decline? The CEO’s continued equity accumulation suggests confidence in a turnaround, but the stock remains highly volatile. Those willing to tolerate short‑term risk may view this period as an opportunity to acquire a significant stake at a low price point, while others may wait for clearer signs of operational progress and financial recovery.